Marketing authorisations granted for Bencium® in the Nordics
Consilient Health are proud to announce the grant of marketing authorisation for Bencium® in Finland, in August 2019 following approvals earlier this year in Sweden and Norway. Bencium® further expands the company’s endocrinology range and sits alongside Benferol® which was launched in the Nordics in 2017.
Henrik Sahl, Consilient Health’s Country Manager for the Nordics commented, “Bencium® is an important addition to our bone health range of products and meets a need identified by Nordic clinicians. The Consilient Health Nordic team are delighted to have received the marketing authorisation grants and looks forward to launching the product.”
View more news and events